Cancer Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
You may also be interested in...
Partnerships between Lilly/Qiagen and BioMarin/Myriad highlight the increasing pace of deals to develop companion diagnostics as the importance of biomarkers and tests to drug development increases. In other deals Clovis buys Eos, Amicus buys Callidus and Versant gives Celgene and Bayer options to acquire drug assets.
Versant is betting a sizable amount of its portfolio on drug assets, instead of full-blown companies, with single buyers holding options to acquire each one.
Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.